Hims & Hers Health (NYSE:HIMS) Shares Gap Up to $11.26

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $11.26, but opened at $11.80. Hims & Hers Health shares last traded at $11.68, with a volume of 3,705,664 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Imperial Capital raised shares of Hims & Hers Health from an "in-line" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research report on Wednesday, February 28th. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a "buy" rating and a $20.00 price target on the stock. Seaport Res Ptn reissued a "buy" rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Piper Sandler boosted their price target on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 27th. Finally, SVB Leerink began coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a "market perform" rating and a $10.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $14.85.

Hims & Hers Health Trading Up 3.5 %

The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -105.91 and a beta of 0.97. The stock's 50 day moving average is $14.01 and its 200 day moving average is $10.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same quarter in the prior year, the business earned ($0.05) EPS. Hims & Hers Health's quarterly revenue was up 47.4% on a year-over-year basis. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.11 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at approximately $494,835.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Andrew Dudum sold 97,208 shares of the company's stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the sale, the chief executive officer now owns 51,653 shares of the company's stock, valued at approximately $494,835.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,080 shares of the company's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the sale, the insider now directly owns 154,345 shares of the company's stock, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. Insiders have sold a total of 736,191 shares of company stock worth $9,733,700 in the last quarter. Corporate insiders own 31.63% of the company's stock.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $48,000. Belpointe Asset Management LLC bought a new position in shares of Hims & Hers Health during the third quarter valued at $76,000. EMC Capital Management raised its stake in shares of Hims & Hers Health by 80.0% during the third quarter. EMC Capital Management now owns 12,000 shares of the company's stock valued at $79,000 after acquiring an additional 5,332 shares during the last quarter. Certuity LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at $109,000. Finally, Corton Capital Inc. bought a new position in shares of Hims & Hers Health during the third quarter valued at $122,000. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.